Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19...(medical technology company providing inn...),Health

Date:1/25/2008

medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also commercialized a series of innovative products through its own direct endovascular sales force. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities including the Company's forecast of operating results for the third quarter and fiscal 2008. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's success in distributing its endovascular products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling KNC related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies, among other important risks. For a more detailed
'/>"/>

SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
3. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
6. Kensey Nash Announces $25 Million Stock Repurchase Program
7. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
8. WellPoint Reports Fourth Quarter and Full Year 2007 Results
9. Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance
10. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
11. Health care reform and 2008 elections: New reports examine candidates plans, publics views